دورية أكاديمية
Adenosinergic Signaling as a Key Modulator of the Glioma Microenvironment and Reactive Astrocytes.
| العنوان: | Adenosinergic Signaling as a Key Modulator of the Glioma Microenvironment and Reactive Astrocytes. |
|---|---|
| المؤلفون: | Debom GN; Programa de Pós-graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil., Rubenich DS; Programa de Pós-graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil., Braganhol E; Programa de Pós-graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.; Instituto de Cardiologia do Rio Grande do Sul, Instituto de Cardiologia - Fundação Universitária de Cardiologia, Porto Alegre, Brazil. |
| المصدر: | Frontiers in neuroscience [Front Neurosci] 2022 Jan 05; Vol. 15, pp. 648476. Date of Electronic Publication: 2022 Jan 05 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101478481 Publication Model: eCollection Cited Medium: Print ISSN: 1662-4548 (Print) Linking ISSN: 1662453X NLM ISO Abbreviation: Front Neurosci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Research Foundation |
| مستخلص: | Astrocytes are numerous glial cells of the central nervous system (CNS) and play important roles in brain homeostasis. These cells can directly communicate with neurons by releasing gliotransmitters, such as adenosine triphosphate (ATP) and glutamate, into the multipartite synapse. Moreover, astrocytes respond to tissue injury in the CNS environment. Recently, astrocytic heterogeneity and plasticity have been discussed by several authors, with studies proposing a spectrum of astrocytic activation characterized by A1 /neurotoxic and A2 /neuroprotective polarization extremes. The fundamental roles of astrocytes in communicating with other cells and sustaining homeostasis are regulated by purinergic signaling. In the CNS environment, the gliotransmitter ATP acts cooperatively with other glial signaling molecules, such as cytokines, which may impact CNS functions by facilitating/inhibiting neurotransmitter release. Adenosine (ADO), the main product of extracellular ATP metabolism, is an important homeostatic modulator and acts as a neuromodulator in synaptic transmission via P1 receptor sensitization. Furthermore, purinergic signaling is a key factor in the tumor microenvironment (TME), as damaged cells release ATP, leading to ADO accumulation in the TME through the ectonucleotidase cascade. Indeed, the enzyme CD73, which converts AMP to ADO, is overexpressed in glioblastoma cells; this upregulation is associated with tumor aggressiveness. Because of the crucial activity of CD73 in these cells, extracellular ADO accumulation in the TME contributes to sustaining glioblastoma immune escape while promoting A2 -like activation. The present review describes the importance of ADO in modulating astrocyte polarization and simultaneously promoting tumor growth. We also discuss whether targeting of CD73 to block ADO production can be used as an alternative cancer therapy. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Debom, Rubenich and Braganhol.) |
| References: | Anal Cell Pathol (Amst). 2020 Jan 8;2020:6283796. (PMID: 32377504) Acta Neuropathol. 2010 Jan;119(1):7-35. (PMID: 20012068) Cell Biosci. 2019 Feb 15;9:19. (PMID: 30815248) ESMO Open. 2017 Feb 22;1(6):e000144. (PMID: 28912963) PLoS One. 2015 Oct 22;10(10):e0140996. (PMID: 26491983) Adv Pharmacol. 2011;61:495-528. (PMID: 21586368) Glia. 2013 May;61(5):724-31. (PMID: 23378051) Stem Cell Investig. 2016 May 12;3:15. (PMID: 27488400) Cell Mol Immunol. 2018 Aug;15(8):737-739. (PMID: 29553137) Nat Neurosci. 2015 Jul;18(7):942-52. (PMID: 26108722) Physiol Rev. 2018 Jan 1;98(1):239-389. (PMID: 29351512) Cancer Chemother Pharmacol. 2020 Jun;85(6):1177-1182. (PMID: 32417936) Glia. 2014 Oct;62(10):1671-86. (PMID: 24895290) Mov Disord. 2019 Jul;34(7):959-969. (PMID: 31136698) Mol Neurobiol. 2018 Aug;55(8):6927-6938. (PMID: 29363044) J Mol Med (Berl). 2020 Jan;98(1):1-10. (PMID: 31650201) Sci Rep. 2016 Jan 12;6:19107. (PMID: 26755200) Elife. 2018 Jan 30;7:. (PMID: 29380725) Neurosci Lett. 2020 Jun 21;730:135016. (PMID: 32371159) J Neurosci. 2013 Nov 20;33(47):18492-502. (PMID: 24259572) J Neurosci. 2019 May 29;39(22):4387-4402. (PMID: 30926752) Nature. 2017 Jan 26;541(7638):481-487. (PMID: 28099414) Glia. 2019 Dec;67(12):2329-2342. (PMID: 31328322) Cells. 2019 Jul 13;8(7):. (PMID: 31337034) Oncotarget. 2018 Jan 25;9(10):9400-9414. (PMID: 29507698) Curr Opin Pharmacol. 2016 Aug;29:7-16. (PMID: 27209048) Trends Mol Med. 2019 Feb;25(2):77-95. (PMID: 30611668) PLoS One. 2012;7(10):e47468. (PMID: 23094051) Mol Cell Biochem. 2012 Jan;359(1-2):315-22. (PMID: 21858682) Glia. 2013 Jul;61(7):1113-21. (PMID: 23625868) Glia. 2011 Aug;59(8):1169-80. (PMID: 21446047) Adv Exp Med Biol. 2016;949:245-261. (PMID: 27714693) Ann Neurol. 2018 Mar;83(3):544-552. (PMID: 29406582) Neuron. 2020 Dec 23;108(6):1025-1044. (PMID: 33065047) Neuroscientist. 2019 Jun;25(3):227-240. (PMID: 29931997) J Cancer. 2017 Feb 25;8(5):761-773. (PMID: 28382138) Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150. (PMID: 28815663) Sci Transl Med. 2015 Mar 4;7(277):277ra30. (PMID: 25739764) Front Immunol. 2018 May 08;9:1004. (PMID: 29867979) J Neuroinflammation. 2012 Aug 16;9:198. (PMID: 22894638) Int J Mol Med. 2008 Jan;21(1):63-7. (PMID: 18097617) Vessel Plus. 2020;4:. (PMID: 32490359) Curr Opin Pharmacol. 2016 Aug;29:17-25. (PMID: 27262778) Front Neurosci. 2021 May 13;15:666710. (PMID: 34054416) Brain Behav. 2014;4(6):903-14. (PMID: 25365803) Front Neurosci. 2015 Apr 28;9:148. (PMID: 25972780) Med Oncol. 2015 Mar;32(3):43. (PMID: 25631631) Mol Neurobiol. 2019 Jun;56(6):4566-4581. (PMID: 30353492) J Biol Chem. 2007 Sep 28;282(39):28749-28758. (PMID: 17627942) Physiol Rev. 2007 Apr;87(2):659-797. (PMID: 17429044) J Neurosci. 2012 May 2;32(18):6391-410. (PMID: 22553043) Curr Diab Rep. 2019 Sep 10;19(10):102. (PMID: 31506846) Mol Imaging. 2020 Jan-Dec;19:1536012120927609. (PMID: 32539522) ASN Neuro. 2019 Jan-Dec;11:1759091419833502. (PMID: 30862176) Adv Exp Med Biol. 2020;1259:155-170. (PMID: 32578176) Nat Rev Neurol. 2018 Aug;14(8):482-495. (PMID: 29985475) Brain. 2019 Mar 1;142(3):586-605. (PMID: 30698736) Glia. 2012 Jul;60(7):1106-16. (PMID: 22499153) J Mol Neurosci. 2018 Aug;65(4):456-466. (PMID: 30030763) Front Pharmacol. 2018 Apr 24;9:399. (PMID: 29740323) Glia. 2020 May;68(5):979-988. (PMID: 31769546) Curr Opin Pharmacol. 2020 Aug;53:126-133. (PMID: 33002857) Physiol Rev. 2014 Oct;94(4):1077-98. (PMID: 25287860) Cancer Cell. 2017 Mar 13;31(3):326-341. (PMID: 28292436) Neuro Oncol. 2018 Jan 10;20(1):37-43. (PMID: 29016805) Trends Pharmacol Sci. 2005 Oct;26(10):511-6. (PMID: 16125796) Exp Neurol. 2016 Jan;275 Pt 3:305-315. (PMID: 25828533) Adv Pharmacol. 2011;61:95-114. (PMID: 21586357) Neurochem Int. 2003 Dec;43(7):621-8. (PMID: 12892649) J Neurosci. 2011 May 11;31(19):6956-62. (PMID: 21562257) J Neurosci Res. 2017 Apr;95(4):1053-1066. (PMID: 27714837) Nat Rev Cancer. 2010 May;10(5):319-31. (PMID: 20414201) J Biol Chem. 2002 Mar 22;277(12):10482-8. (PMID: 11790776) Cancer Discov. 2020 Jan;10(1):40-53. (PMID: 31732494) Trends Neurosci. 2019 Dec;42(12):885-898. (PMID: 31704181) Neurobiol Dis. 2004 Jun;16(1):1-13. (PMID: 15207256) Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):E197-205. (PMID: 22167804) Immunity. 2017 Jun 20;46(6):957-967. (PMID: 28636962) Int J Mol Sci. 2018 Feb 01;19(2):. (PMID: 29389898) Nat Rev Cancer. 2018 Oct;18(10):601-618. (PMID: 30006588) Glia. 2019 May;67(5):779-790. (PMID: 30240060) Trends Neurosci. 2009 Dec;32(12):638-47. (PMID: 19782411) Oncol Rep. 2014 Feb;31(2):819-27. (PMID: 24297662) Neuroscience. 2016 May 26;323:67-75. (PMID: 25727638) Neurooncol Adv. 2020 May 06;2(1):vdaa056. (PMID: 32642708) Cancer Immunol Immunother. 2020 Sep;69(9):1801-1812. (PMID: 32350590) Cells. 2020 Jul 03;9(7):. (PMID: 32635260) Cells. 2019 Dec 30;9(1):. (PMID: 31906023) Sci Am. 2009 Dec;301(6):84-90, 92. (PMID: 20058644) Nat Rev Clin Oncol. 2020 Oct;17(10):611-629. (PMID: 32514148) Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):. (PMID: 29158308) Int J Mol Sci. 2020 Jun 02;21(11):. (PMID: 32498400) J Neurochem. 2016 Dec;139(6):1019-1055. (PMID: 27365148) Sci Rep. 2015 Jan 19;5:7847. (PMID: 25597401) Neuron. 2008 Jan 10;57(1):121-34. (PMID: 18184569) Front Immunol. 2015 Feb 24;6:66. (PMID: 25759690) Trends Neurosci. 2009 Feb;32(2):79-87. (PMID: 19135728) Sci Transl Med. 2019 Oct 16;11(514):. (PMID: 31619545) J Cell Physiol. 2019 May;234(5):5700-5721. (PMID: 30378106) J Biol Chem. 2013 Sep 27;288(39):28058-67. (PMID: 23926109) Nat Rev Neurosci. 2013 May;14(5):311-21. (PMID: 23595014) Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):333-340. (PMID: 28554667) Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7. (PMID: 16916931) Neuroscience. 2006;138(2):421-32. (PMID: 16414200) Int J Mol Sci. 2020 Sep 30;21(19):. (PMID: 33007835) J Neurosci. 1999 Jan 15;19(2):520-8. (PMID: 9880572) Glia. 2019 May;67(5):915-934. (PMID: 30632636) Biol Psychiatry. 2015 Dec 1;78(11):763-74. (PMID: 25869810) Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1896-E1905. (PMID: 29437957) J Mol Med (Berl). 2014 Dec;92(12):1283-92. (PMID: 25120128) Int Rev Neurobiol. 1985;27:63-139. (PMID: 2867982) Mol Neurobiol. 2019 May;56(5):3260-3279. (PMID: 30117104) Nucleosides Nucleotides Nucleic Acids. 2018;37(12):709-716. (PMID: 30623751) J Clin Invest. 2020 Nov 2;130(11):5629-5637. (PMID: 32870821) Nat Commun. 2014 Jun 19;5:4196. (PMID: 24943270) J Mol Neurosci. 2015 Apr;55(4):898-911. (PMID: 25326791) Lab Invest. 2017 May;97(5):498-518. (PMID: 28287634) Immune Netw. 2019 Aug 27;19(4):e23. (PMID: 31501711) Front Pharmacol. 2018 Jun 14;9:627. (PMID: 29962948) J Neurosci. 2014 Nov 12;34(46):15482-9. (PMID: 25392515) Cancers (Basel). 2020 Jul 19;12(7):. (PMID: 32707733) J Neurosci. 2012 Mar 28;32(13):4417-25. (PMID: 22457491) J Neurosci. 2003 May 15;23(10):4034-43. (PMID: 12764090) Science. 2015 Apr 3;348(6230):74-80. (PMID: 25838376) J Immunol. 2012 Aug 1;189(3):1303-10. (PMID: 22753942) Nat Neurosci. 2017 Nov;20(11):1540-1548. (PMID: 28945222) J Neurochem. 2003 Aug;86(4):1051-4. (PMID: 12887702) J Biol Chem. 2003 Jan 10;278(2):1354-62. (PMID: 12414798) Neurochem Int. 2019 Dec;131:104538. (PMID: 31430518) PLoS One. 2015 Aug 11;10(8):e0134934. (PMID: 26263491) Cancer Res. 2006 Sep 1;66(17):8550-7. (PMID: 16951167) Int J Mol Sci. 2019 Nov 14;20(22):. (PMID: 31739402) Glia. 2019 Dec;67(12):2221-2247. (PMID: 31429127) Cold Spring Harb Perspect Med. 2017 Sep 1;7(9):. (PMID: 28289244) Mol Brain. 2019 May 9;12(1):48. (PMID: 31072410) Nature. 2016 Nov 17;539(7629):428-432. (PMID: 27828941) Pharmacol Res. 2020 Dec;162:105253. (PMID: 33080321) Nat Neurosci. 2016 Jan;19(1):20-7. (PMID: 26713745) Glia. 2020 Feb;68(2):316-327. (PMID: 31509308) Pharmacol Rev. 2011 Mar;63(1):1-34. (PMID: 21303899) Neurochem Res. 2010 Sep;35(9):1434-44. (PMID: 20577800) Nucleosides Nucleotides Nucleic Acids. 2017 Jan 2;36(1):7-30. (PMID: 27759477) Fluids Barriers CNS. 2015 Sep 02;12:20. (PMID: 26330053) Cancer Lett. 2019 Apr 1;446:112-122. (PMID: 30660649) Front Pharmacol. 2018 Mar 01;9:153. (PMID: 29545748) Int J Mol Sci. 2020 Aug 20;21(17):. (PMID: 32825423) Int J Mol Sci. 2019 Jul 30;20(15):. (PMID: 31366130) Prog Neurobiol. 2019 Mar;174:36-52. (PMID: 30599178) Neurobiol Dis. 2018 Oct;118:142-154. (PMID: 30026035) Mol Neurobiol. 2020 Feb;57(2):635-649. (PMID: 31407144) Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17513-8. (PMID: 17090684) Neurosurg Rev. 2019 Jun;42(2):263-275. (PMID: 29138949) J Neuropathol Exp Neurol. 2014 May;73(5):414-24. (PMID: 24709676) Nat Commun. 2019 Jun 11;10(1):2541. (PMID: 31186414) Future Oncol. 2017 Dec;13(28):2583-2592. (PMID: 29198150) Cells. 2019 Oct 30;8(11):. (PMID: 31671624) Tumour Biol. 2016 Jan;37(1):61-9. (PMID: 26493995) N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009) Front Neurosci. 2019 Sep 04;13:925. (PMID: 31551688) Immunol Rev. 2017 Mar;276(1):121-144. (PMID: 28258700) J Neurochem. 2020 May;153(4):455-467. (PMID: 31811731) Neurochem Res. 2016 Jul;41(7):1774-83. (PMID: 27038930) |
| فهرسة مساهمة: | Keywords: A2-like astrocyte; CD73; adenosine; glioblastoma; tumor microenvironment; tumor-associated astrocyte |
| تواريخ الأحداث: | Date Created: 20220124 Latest Revision: 20220125 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8766410 |
| DOI: | 10.3389/fnins.2021.648476 |
| PMID: | 35069091 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1662-4548 |
|---|---|
| DOI: | 10.3389/fnins.2021.648476 |